Cytokine profiles in schizophrenic patients treated with risperidone: A 3-month follow-up study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 1, 2002, Pages 33-39

  Cazzullo, Carlo L ^a   Sacchetti, Emilio ^b   Galluzzo, Alessandro ^b   Panariello, Adelaide ^b   Adorni, Andrea ^b   Pegoraro, Marco ^b   Bosis, Simona ^c   Colombo, Fulvia ^c   Trabattoni, Daria ^c   Zagliani, Arianna ^c   Clerici, Mario ^c  

^a Fondazione Legrenzi   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c DISP LITA Vialba   (Italy)

Author keywords

Antipsychotics; Cytokines; Risperidone; Schizophrenia

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; RISPERIDONE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE DURATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; MALE; REFERENCE VALUES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX CHARACTERISTICS; TIME FACTORS;

EID: 0036139673     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00221-4     Document Type: Article

References (41)

1. Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro
2. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour
3. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease
4. Cytokine production and surface markers expression in acute and stable multiple sclerosis. Dysregulated IL-12 production and augmented SLAM-expressing lymphocytes in acute multiple sclerosis
5. Antinuclear antibodies and lupus cells in 600 hospitalized phenotiazine treated patients
6. Increased serum interleukin 2 receptor levels in schizophrenic and brain damaged subjects
7. Clinical and laboratory evidence of autoimmunity in acute schizophrenia
8. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness
9. Reply on: Pollmacher, T., Hinze-Selch, D., Mullington, J. and Holsboer, F.: Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors
10. Clozapine, cytokines, fever and sleep
11. Effects of clozapine on in vitro immune parameters: A longitudinal study in clozapine-treated schizophrenic patients
12. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia
13. IL-2 responsiveness of lectin-induced lymphoblasts: Soluble IL-2 receptors release and differential in vitro effects of immunosuppressants
14. Decreased interleukin-2 production in Korean schizophrenic patients
15. Elevated levels of interleukin-2 in neuroleptic-free schizophrenics
16. A new five-factor model of schizophrenia
17. Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine
18. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers
19. Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol
20. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs
21. In vivo immunomodulatory effects of clozapine in schizophrenia
22. Effects of short-term administration of antipsychotic drugs on lymphocytes subsets in schizophrenic patients
23. Reduced lymphocyte response to PHA and OKT3 in drug-free and neuroleptic treated chronic schizophrenics
24. Cellular immunity in schizophrenic patients before and during neuroleptic therapy
25. T-cells and psychopathology in schizophrenia: Relationship to the outcome of neuroleptic therapy
26. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia
27. Increased production of Interleukin-2, IL-2 but not soluble interleukin-2 receptor, sIL-2R in unmedicated patients with schizophrenia and schizophreniform disorder
28. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors
29. Effects of clozapine on plasma cytokine receptor levels
30. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol
31. Elevated levels of soluble interleukin-2 receptors in schizophrenia
32. The effect of typical and atypical neuroleptics on mitogen-induced T-lymphocyte responsiveness
33. Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins
34. Increased soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients
35. Immunological dysfunction in schizophrenia: A systematic approach
36. Inhibition of chlorpromazine of lymphokine-specific m-RNA expression in human thymocytes
37. Inhibition of chlorpromazine of lymphokine-specific mRNA expression in human thymocytes
38. Aberrant T cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production
39. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients
40. Immunologic and coagulation disorders in chlorpromazine-treated patients